comparemela.com

Latest Breaking News On - Tobias mac - Page 1 : comparemela.com

EU Malaria Fund Enters Post-investment Period

Strong backing for vaccine production for Africa

Strong backing for vaccine production for Africa
guardian.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from guardian.ng Daily Mail and Mail on Sunday newspapers.

Strong backing for vaccine production for Africa

Strong backing for vaccine production for Africa
africanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from africanews.com Daily Mail and Mail on Sunday newspapers.

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa

Private and Public Sector Join Forces Under the Umbrella of the kENUP Foundation: BioNTech Announces Project to Develop the First mRNA-Based Prophylactic Malaria vaccine, and the set-up of Manufacturing Infrastructures in Africa
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2

Press release content from Business Wire. The AP news staff was not involved in its creation. AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 January 25, 2021 GMT AchilleS Vaccines Completes Industrial Development of Promising Treatment Against SARS-CoV-2 (Photo: AchilleS Vaccines) KALKARA, Malta & SIENA, Italy (BUSINESS WIRE) Jan 25, 2021 Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.